Capricor Therapeutics, Inc. (CAPR) Trades Higher on News of $4.2M Grant from National Institutes of Health
Shares of Capricor Therapeutics (NASDAQ: CAPR) spiked 7% at the opening bell after the company announced that it has received a grant of up to $4.2 million from the National Institutes of Health to study CAP-2003 for hypoplastic left heart syndrome (HLHS). "We are excited to be part of this research effort to understand how CDC Exosomes, which are believed to be responsible for the regenerative effect of cardiosphere-derived cells, may be useful in the treatment of a serious congenital heart condition. We look forward to seeing if CAP-2003 can improve heart function, initially in pre-clinical models, and eventually in…